Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) Given Consensus Rating of “Moderate Buy” by Brokerages

Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) has been assigned a consensus recommendation of “Moderate Buy” from the seven brokerages that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $16.95.

Several research firms have issued reports on BWAY. Weiss Ratings reiterated a “buy (b-)” rating on shares of Brainsway in a research report on Tuesday, July 21st. Zacks Research lowered shares of Brainsway from a “strong-buy” rating to a “hold” rating in a research report on Tuesday. HC Wainwright restated a “buy” rating and set a $14.00 target price on shares of Brainsway in a research report on Friday, July 17th. BTIG Research upped their price target on shares of Brainsway from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Wednesday. Finally, LADENBURG THALM/SH SH increased their price target on shares of Brainsway from $18.00 to $18.80 and gave the company a “buy” rating in a report on Thursday.

Key Brainsway News

Here are the key news stories impacting Brainsway this week:

• Positive Sentiment: Strong Q2 performance: BrainsWay reported adjusted EPS of $0.14, beating the $0.10 consensus estimate, while revenue rose 35% year over year to a record $17.1 million, above expectations of $16.54 million. The company also reported a 15.68% net margin and 12.28% return on equity. BrainsWay Reports Second Quarter 2026 Financial Results and Operational Highlights
• Positive Sentiment: Raised full-year outlook: Management forecast 2026 revenue of $68 million to $70 million, modestly above the $67.8 million analyst consensus. The improved outlook reinforces expectations for continued growth in BrainsWay’s transcranial magnetic stimulation business. BrainsWay earnings report
• Positive Sentiment: Analysts raised targets: BTIG Research increased its price target from $18 to $20 and maintained a Buy rating. Ladenburg Thalmann also raised its target from $18 to $18.80 and assigned a Buy rating, indicating further potential upside from recent trading levels. BTIG raises BrainsWay price target
• Neutral Sentiment: Momentum near a new high: BWAY recently reached a new 1-year high following the earnings beat, reflecting strong momentum but also potentially increasing profit-taking risk after the rally. Brainsway sets new 1-year high
• Negative Sentiment: Rating downgrade: Zacks Research cut BrainsWay from “strong buy” to “hold,” providing a counterweight to the favorable earnings news and other analysts’ target increases. Zacks downgrade of BrainsWay

Brainsway Trading Down 0.8%

NASDAQ BWAY opened at $16.47 on Friday. The stock has a market capitalization of $660.94 million, a price-to-earnings ratio of 37.43 and a beta of 1.24. The business’s 50 day moving average is $15.13 and its two-hundred day moving average is $14.36. Brainsway has a 12-month low of $6.26 and a 12-month high of $17.40.

Brainsway (NASDAQ:BWAY) last posted its quarterly earnings results on Wednesday, August 12th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.03). Brainsway had a net margin of 15.65% and a return on equity of 13.01%. The business had revenue of $17.11 million during the quarter, compared to analyst estimates of $16.54 million. Equities analysts forecast that Brainsway will post 0.33 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Masters Capital Management LLC lifted its position in shares of Brainsway by 65.0% during the 1st quarter. Masters Capital Management LLC now owns 1,650,000 shares of the company’s stock valued at $21,928,000 after acquiring an additional 650,000 shares during the period. Renaissance Technologies LLC grew its holdings in shares of Brainsway by 87.2% in the 1st quarter. Renaissance Technologies LLC now owns 518,420 shares of the company’s stock worth $6,890,000 after acquiring an additional 241,560 shares during the period. Sei Investments Co. grew its holdings in shares of Brainsway by 262.5% in the 1st quarter. Sei Investments Co. now owns 226,378 shares of the company’s stock worth $3,009,000 after acquiring an additional 163,925 shares during the period. Y.D. More Investments Ltd increased its stake in Brainsway by 136.6% in the 1st quarter. Y.D. More Investments Ltd now owns 272,004 shares of the company’s stock valued at $3,615,000 after purchasing an additional 157,042 shares in the last quarter. Finally, ARK Investment Management LLC acquired a new position in Brainsway during the fourth quarter worth $2,422,000. 30.11% of the stock is owned by hedge funds and other institutional investors.

Brainsway Company Profile

Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway’s technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.

The company’s flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.